NR1H4 and metabolic dysfunction-associated steatohepatitis: Previous studies have showed that the administration of probiotics altered the bile acid composition (40), and bile acid-based therapies, including hepatic FXR agonists, FGF15/19 analog, are considered for NASH therapy (31).